941-485-1121
The enVista monofocal IOL delivers superb visual acuity, consistent performance, and outstanding patient outcomes. It is the clear choice for consistent visual excellence.
Because the eye is not a perfect optical system, due to its visual axis not passing through the center of the cornea, pupil, or lens, Dr. Stephenson has selected the enVista lens as her “go to” IOL. The enVista monofocal IOL has a unique set of features that help compensate for the eye’s natural imperfections and delivers outstanding visual outcomes to a wide range of patients.
The enVista Toric IOL is the Clear Choice for Exceptional Astigmatism Management.
The toric version of the enVista IOL offers exacting astigmatism correction with dependable stability and pristine visual clarity. It all comes together in the proven enVista platform. Combining an advanced aberration-free optic with a distinctive design, the enVista toric IOL platform is proven to deliver exceptional rotational stability and excellent outcomes to cataract patients with astigmatism.
By correcting a patient’s astigmatism during cataract surgery, the patient will be less dependent on eyeglasses for their distance vision.
The Apthera IOL is an innovative lens that can greatly improve vision for individuals undergoing cataract surgery. This advanced intraocular lens (IOL) is designed to provide clear vision at various distances, reducing the need for glasses or contact lenses.
The Apthera IOL incorporates cutting-edge technology to enhance visual acuity and minimize visual disturbances, such as halos or glare. With its ability to adapt to different lighting conditions, this lens offers a natural and comfortable visual experience.
In mid-2012, the Food and Drug Administration approved the enVista hydrophobic acrylic IOL (Bausch + Lomb). This lens is the only FDA-approved lens with labeling that states, “no glistenings of any grade were reported for any subject at any visit in the clinical study.”
“The FDA approved the enVista IOL as glistening-free following a 122-eye clinical trial involving six sites,” says Peter Heiner, MD. Dr. Stephenson is one of the first Florida cataract surgeons to implant this new breakthrough IOL. Please feel free to consult Dr. Stephenson directly about this new lens and the benefits this is bringing to her patients.
